Glycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors

Author(s): Pankaj Wadhwa, Priti Jain, Hemant R. Jadhav*

Journal Name: Current Topics in Medicinal Chemistry

Volume 20 , Issue 17 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Glycogen Synthase Kinase 3 (GSK3) is one of the Serine/Threonine protein kinases, which has gained a lot of attention for its role in a variety of pathways. It has two isoforms, GSK3α and GSK3β. However, GSK3β is highly expressed in different areas of the brain and has been implicated in Alzheimer’s disease as it is involved in tau phosphorylation. Due to its high specificity concerning substrate recognition, GSK3 has been considered as an important target. In the last decade, several GSK3 inhibitors have been reported and two molecules are in clinical trials. This review collates the information published in the last decade about the role of GSK3 in Alzheimer’s disease and progress in the development of its inhibitors. Using this collated information, medicinal chemists can strategize and design novel GSK3 inhibitors that could be useful in the treatment of Alzheimer’s disease.

Keywords: Glycogen Synthase Kinase 3, Alzheimer`s disease, Cancer, Inflammation, Inhibitors, Tideglusib.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [1522 - 1534]
Pages: 13
DOI: 10.2174/1568026620666200516153136
Price: $65

Article Metrics

PDF: 27